ROCKET PHARMACEUTICALS, INC.RCKTEarnings & Financial Report
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing first-in-class adeno-associated virus (AAV) and lentiviral-based gene therapies for rare, orphan genetic disorders with high unmet medical need. It primarily operates across the U.S. and European markets, with pipeline candidates targeting hematologic, neurological, and pediatric genetic conditions.
RCKT Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-44.0M
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.38
ROCKET PHARMACEUTICALS, INC. Q4 FY2025 Financial Summary
ROCKET PHARMACEUTICALS, INC. reported revenue of $0 for Q4 FY2025, with a net profit of N/A (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
ROCKET PHARMACEUTICALS, INC. Annual Revenue by Year
ROCKET PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
ROCKET PHARMACEUTICALS, INC. Quarterly Revenue & Net Profit History
ROCKET PHARMACEUTICALS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | N/A | N/A |
| Q3 FY2025 | $0 | — | $-50.3M | N/A |
| Q2 FY2025 | $0 | — | $-68.9M | N/A |
| Q1 FY2025 | $0 | — | $-61.3M | N/A |
| Q4 FY2024 | $0 | — | N/A | N/A |
| Q3 FY2024 | $0 | — | $-66.7M | N/A |
| Q2 FY2024 | $0 | — | $-69.6M | N/A |
| Q1 FY2024 | $0 | — | $-62.1M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $499.4M | $446.4M | $393.7M | $527.7M | $471.1M | $421.0M | $368.0M | $330.4M |
| Liabilities | $57.9M | $61.8M | $63.9M | $64.5M | $58.9M | $66.8M | $54.4M | $53.2M |
| Equity | $441.5M | $384.6M | $329.8M | $463.2M | $412.1M | $354.2M | $313.7M | $277.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-56.9M | $-53.8M | $-52.1M | $-46.9M | $-55.8M | $-49.0M | $-50.4M | $-34.8M |